Ozone is one of 394 small molecule programs targeting Myofascial Pain Syndrome. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
1931 competitors in COVID-19
Ozone
COVID-19 Vaccine
Stivarga
Aimovig
Calciferol
Activella
Proventil
Precedex
SARS-COV-2 VACCINE
Biological Collection
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details